J B Chemicals And Pharmaceutical Share Price
Sector: Biotechnology & Drugs
1704.00 +40.05 (2.41%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1645.00
Today’s High
1718.90
52 Week Low
1303.00
52 Week High
2029.00
1702.10 +38.20 (2.30%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1645.00
Today’s High
1718.70
52 Week Low
1385.75
52 Week High
2030.00
Key Metrics
- Market Cap (In Cr) 26555.52
- Beta 0.23
- Div. Yield (%) 0.93
- P/B 7.54
- TTM P/E 38.24
- Peg Ratio 2.15
- Sector P/E 24.5
- D/E 0
- Open Price 1671.9
- Prev Close 1663.95
J B Chemicals And Pharmaceutical Analysis
Price Analysis
-
1 Week6.85%
-
3 Months1.41%
-
6 Month-0.92%
-
YTD-9.77%
-
1 Year-9.72%
Risk Meter
- 32% Low risk
- 32% Moderate risk
- 32% Balanced Risk
- 32% High risk
- 32% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 7
- 7
- 7
- 7
- Buy
- 4
- 2
- 2
- 2
- Hold
- 1
- 1
- 1
- 1
- Sell
- 0.00
- 1
- 1
- 1
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 12
- 11
- 11
- 11
J B Chemicals And Pharmaceutical News
Q4 results today: Tata Power, Eicher Motors, Lupin, Shree Cements on May 14
1 min read . 14 May 2025JB Chemicals shares slump 7% after 90 lakh shares change hands in a block deal
2 min read . 27 Mar 2025KKR plans to sell 7% in JB Chemicals with an option to offload more
2 min read . 26 Mar 2025J B Chemicals And Pharmaceutical Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 3917.99
- Selling/ General/ Admin Expenses Total
- 687.61
- Depreciation/ Amortization
- 171.04
- Other Operating Expenses Total
- 881.99
- Total Operating Expense
- 3057.19
- Operating Income
- 860.8
- Net Income Before Taxes
- 887.39
- Net Income
- 659.58
- Diluted Normalized EPS
- 41.56
- Period
- 2025
- Total Assets
- 4273.78
- Total Liabilities
- 840.46
- Total Equity
- 3433.32
- Tangible Book Valueper Share Common Eq
- 132.24
- Period
- 2025
- Cashfrom Operating Activities
- 902.45
- Cashfrom Investing Activities
- -295.89
- Cashfrom Financing Activities
- -579.68
- Net Changein Cash
- 26.87
- Period
- 2024
- Total Revenue
- 3484.18
- Selling/ General/ Admin Expenses Total
- 1231.89
- Depreciation/ Amortization
- 138.32
- Other Operating Expenses Total
- 68.55
- Total Operating Expense
- 2729.79
- Operating Income
- 754.39
- Net Income Before Taxes
- 751.51
- Net Income
- 552.63
- Diluted Normalized EPS
- 34.86
- Period
- 2024
- Total Assets
- 3994.13
- Total Liabilities
- 1070.8
- Total Equity
- 2923.33
- Tangible Book Valueper Share Common Eq
- 95.2
- Period
- 2024
- Cashfrom Operating Activities
- 800.61
- Cashfrom Investing Activities
- -403.83
- Cashfrom Financing Activities
- -385.49
- Net Changein Cash
- 11.28
- Period
- 2023
- Total Revenue
- 3149.28
- Selling/ General/ Admin Expenses Total
- 1093.9
- Depreciation/ Amortization
- 114.41
- Other Operating Expenses Total
- 72.2
- Total Operating Expense
- 2556.85
- Operating Income
- 592.43
- Net Income Before Taxes
- 555.23
- Net Income
- 409.84
- Diluted Normalized EPS
- 26.17
- Period
- 2023
- Total Assets
- 3553.87
- Total Liabilities
- 1073.52
- Total Equity
- 2480.35
- Tangible Book Valueper Share Common Eq
- 71.12
- Period
- 2023
- Cashfrom Operating Activities
- 625.61
- Cashfrom Investing Activities
- -961.79
- Cashfrom Financing Activities
- 356.54
- Net Changein Cash
- 20.39
- Period
- 2022
- Total Revenue
- 2424.24
- Selling/ General/ Admin Expenses Total
- 881.68
- Depreciation/ Amortization
- 72.66
- Other Operating Expenses Total
- 60.46
- Total Operating Expense
- 1949.65
- Operating Income
- 474.6
- Net Income Before Taxes
- 504.9
- Net Income
- 385.36
- Diluted Normalized EPS
- 24.79
- Period
- 2022
- Total Assets
- 2607.4
- Total Liabilities
- 473.28
- Total Equity
- 2134.12
- Tangible Book Valueper Share Common Eq
- 90.92
- Period
- 2022
- Cashfrom Operating Activities
- 170.13
- Cashfrom Investing Activities
- 2.32
- Cashfrom Financing Activities
- -138.39
- Net Changein Cash
- 34.07
- Period
- 2021
- Total Revenue
- 2042.52
- Selling/ General/ Admin Expenses Total
- 635.92
- Depreciation/ Amortization
- 68.67
- Other Operating Expenses Total
- 70.39
- Total Operating Expense
- 1555.01
- Operating Income
- 487.51
- Net Income Before Taxes
- 596.89
- Net Income
- 447.96
- Diluted Normalized EPS
- 26.43
- Period
- 2021
- Total Assets
- 2238.12
- Total Liabilities
- 428.39
- Total Equity
- 1809.72
- Tangible Book Valueper Share Common Eq
- 111.29
- Period
- 2021
- Cashfrom Operating Activities
- 314.78
- Cashfrom Investing Activities
- -230.68
- Cashfrom Financing Activities
- -87.42
- Net Changein Cash
- -3.28
- Period
- 2020
- Total Revenue
- 1774.73
- Selling/ General/ Admin Expenses Total
- 611.56
- Depreciation/ Amortization
- 66.32
- Other Operating Expenses Total
- 63.05
- Total Operating Expense
- 1466.74
- Operating Income
- 307.99
- Net Income Before Taxes
- 348.89
- Net Income
- 272.05
- Diluted Normalized EPS
- 17.39
- Period
- 2020
- Total Assets
- 1820.56
- Total Liabilities
- 385.07
- Total Equity
- 1435.49
- Tangible Book Valueper Share Common Eq
- 87.49
- Period
- 2020
- Cashfrom Operating Activities
- 275.75
- Cashfrom Investing Activities
- 23.93
- Cashfrom Financing Activities
- -306.05
- Net Changein Cash
- -6.39
- Period
- 2019
- Total Revenue
- 1643.2
- Selling/ General/ Admin Expenses Total
- 584.7
- Depreciation/ Amortization
- 55.64
- Other Operating Expenses Total
- 59.64
- Total Operating Expense
- 1384.58
- Operating Income
- 258.62
- Net Income Before Taxes
- 286.99
- Net Income
- 193.47
- Diluted Normalized EPS
- 11.67
- Period
- 2019
- Total Assets
- 1791.95
- Total Liabilities
- 311.83
- Total Equity
- 1480.12
- Tangible Book Valueper Share Common Eq
- 87.47
- Period
- 2019
- Cashfrom Operating Activities
- 193.08
- Cashfrom Investing Activities
- -26.89
- Cashfrom Financing Activities
- -155.29
- Net Changein Cash
- 10.9
- Period
- 2025-03-31
- Total Revenue
- 949.48
- Selling/ General/ Admin Expenses Total
- 176.82
- Depreciation/ Amortization
- 46.44
- Other Operating Expenses Total
- 224.58
- Total Operating Expense
- 769.48
- Operating Income
- 180
- Net Income Before Taxes
- 193.03
- Net Income
- 145.69
- Diluted Normalized EPS
- 9.17
- Period
- 2025-03-31
- Total Assets
- 4273.78
- Total Liabilities
- 840.46
- Total Equity
- 3433.32
- Tangible Book Valueper Share Common Eq
- 132.24
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 902.45
- Cashfrom Investing Activities
- -295.89
- Cashfrom Financing Activities
- -579.68
- Net Changein Cash
- 26.87
- Period
- 2024-12-31
- Total Revenue
- 963.49
- Selling/ General/ Admin Expenses Total
- 173.31
- Depreciation/ Amortization
- 41.94
- Other Operating Expenses Total
- 218.93
- Total Operating Expense
- 750.92
- Operating Income
- 212.57
- Net Income Before Taxes
- 217.99
- Net Income
- 162.49
- Diluted Normalized EPS
- 10.24
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 1000.62
- Selling/ General/ Admin Expenses Total
- 170.57
- Depreciation/ Amortization
- 41.88
- Other Operating Expenses Total
- 221.11
- Total Operating Expense
- 771.98
- Operating Income
- 228.64
- Net Income Before Taxes
- 236.53
- Net Income
- 174.57
- Diluted Normalized EPS
- 11
- Period
- 2024-09-30
- Total Assets
- 4029.41
- Total Liabilities
- 817.18
- Total Equity
- 3212.23
- Tangible Book Valueper Share Common Eq
- 115.66
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 377.63
- Cashfrom Investing Activities
- 9.57
- Cashfrom Financing Activities
- -385.54
- Net Changein Cash
- 1.67
- Period
- 2024-06-30
- Total Revenue
- 1004.4
- Selling/ General/ Admin Expenses Total
- 166.91
- Depreciation/ Amortization
- 40.78
- Other Operating Expenses Total
- 217.37
- Total Operating Expense
- 764.81
- Operating Income
- 239.59
- Net Income Before Taxes
- 239.84
- Net Income
- 176.83
- Diluted Normalized EPS
- 11.16
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 861.73
- Selling/ General/ Admin Expenses Total
- 152.7
- Depreciation/ Amortization
- 40.74
- Other Operating Expenses Total
- 210.63
- Total Operating Expense
- 704.35
- Operating Income
- 157.38
- Net Income Before Taxes
- 164.6
- Net Income
- 126.16
- Diluted Normalized EPS
- 7.83
- Period
- 2024-03-31
- Total Assets
- 3994.13
- Total Liabilities
- 1070.8
- Total Equity
- 2923.33
- Tangible Book Valueper Share Common Eq
- 95.2
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 800.61
- Cashfrom Investing Activities
- -403.83
- Cashfrom Financing Activities
- -385.49
- Net Changein Cash
- 11.28
- Period
- 2023-12-31
- Total Revenue
- 844.51
- Selling/ General/ Admin Expenses Total
- 151.68
- Depreciation/ Amortization
- 34.03
- Other Operating Expenses Total
- 196.08
- Total Operating Expense
- 655.42
- Operating Income
- 189.09
- Net Income Before Taxes
- 183.95
- Net Income
- 133.57
- Diluted Normalized EPS
- 8.46
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
J B Chemicals And Pharmaceutical Technical
Moving Average
SMA
- 5 Day1607.69
- 10 Day1571.28
- 20 Day1590.57
- 50 Day1591.98
- 100 Day1674.12
- 300 Day1769.24
J B Chemicals And Pharmaceutical Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Piramal Pharma
- 205.75
- 0.15
- 0.07
- 307.85
- 135.85
- 27277.27
- Syngene International
- 628.65
- -13.3
- -2.07
- 960
- 598.55
- 25305.48
- J B Chemicals And Pharmaceutical
- 1704
- 40.05
- 2.41
- 2029
- 1303
- 26555.52
- Gland Pharma
- 1498.5
- 14.35
- 0.97
- 2220.95
- 1200
- 24715.69
- Wockhardt
- 1325
- -34.35
- -2.53
- 1678.6
- 489.2
- 21528.46
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Piramal Pharma
- 301.28
- 3.33
- -
- -
- Syngene International
- 54.97
- 5.48
- 13.02
- 15.03
- J B Chemicals And Pharmaceutical
- 39.63
- 7.47
- 20.84
- 16.36
- Gland Pharma
- 31.34
- 2.77
- 14.89
- 22.92
- Wockhardt
- -
- 6.08
- -10.63
- -12.7
J B Chemicals And Pharmaceutical Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 14-May-25
- Audited Results & Final Dividend
- 04-Feb-25
- Quarterly Results & Interim Dividend
- 06-Nov-24
- Quarterly Results
- 08-Aug-24
- Quarterly Results
- 17-May-24
- Audited Results & Final Dividend
- 06-Feb-24
- Quarterly Results & Interim Dividend
- 07-Nov-23
- Quarterly Results
- 09-Aug-23
- Quarterly Results
- 24-May-23
- Audited Results, Dividend & Stock Split
- 08-Feb-23
- Quarterly Results & Interim Dividend
- Meeting Date
- Announced on
- Purpose
- 21-Aug-24
- 26-Jul-24
- AGM
- 07-Jul-24
- 05-Jun-24
- POM
- 09-Apr-24
- 11-Mar-24
- POM
- 22-Dec-23
- 20-Nov-23
- POM
- 24-Aug-23
- 28-Jul-23
- AGM
- 09-Sept-21
- 10-Aug-21
- AGM
- 02-Aug-21
- 02-Jul-21
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 14-May-25
- -
- -
- 7
- 05-Feb-25
- 08-Feb-25
- 07-Feb-25
- 8.5
- 17-May-24
- 14-Aug-24
- 14-Aug-24
- 6.75
- 06-Feb-24
- 16-Feb-24
- 16-Feb-24
- 5.5
- 29-May-23
- -
- 17-Aug-23
- 9.25
- 08-Feb-23
- 18-Feb-23
- 17-Feb-23
- 8.5
- 14-Feb-22
- 24-Feb-22
- 23-Feb-22
- 8.5
- 16-Jun-21
- -
- 01-Sept-21
- 8
- 10-Feb-21
- 22-Feb-21
- 18-Feb-21
- 8.5

- Ex-Splits
- Old FV
- New FV
- Description
- 18-Sept-23
- 2
- 1
- Stock split from Rs. 2/- to 1/-.
